Ilaria Spoletini

Ilaria Spoletini

Auto-generated profile, based on publicly available information

Ilaria Spoletini

IRCCS San Raffaele, Rome, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2019 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Closed access
HDHeinz Drexel
Heinz Drexel
ACAndrew J S Coats
Andrew J S Coats
ISIlaria Spoletini
Ilaria Spoletini
Claudio BilatoClaudio Bilato
Claudio Bilato
VMVincenzo Mollace
Vincenzo Mollace
GRGiuseppe M C Rosano
Giuseppe M C Rosano
Benefits and safety on statins have been well-established over 20 years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the ESC Working Group on Cardiovascular Pharmacotherapy in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe.

14 September 2022 in ESC Heart Failure
Verified
Journal Article
Open access
GRGiuseppe Rosano
Giuseppe Rosano
MRMaria Angeles Rodriguez-Martinez
Maria Angeles Rodriguez-Martinez
ISIlaria Spoletini
Ilaria Spoletini
PRPedro-Antonio Regidor
Pedro-Antonio Regidor
Obesity and oestrogen containing contraceptive products are well-known independent cardiovascular risk factors. However, a significant number of obese women continue to receive prescriptions of hormonal products that contain oestrogens for their contraception. We have conducted a narrative review to discuss the latest evidence, ongoing research, and controversial issues on the synergistic effect of obesity and contraceptive use, in terms of cardiovascular risk. There is compelling evidence of an interplay between obesity and contraception in increasing cardiovascular risk. Women who present both obesity and use of combined oral contraceptives (COCs) have a greater risk (between 12 and 24 times) to develop venous thromboembolism than non-obese non-COC users. Data here discussed offer new insights to increase clinicians' awareness on the cardiovascular risk in the clinical management of obese women. The synergistic effect of obesity and COCs on deep venous thrombosis risk must be considered when prescribing hormonal contraception. Progestin-only products are a safer alternative to COCs in patients with overweight or obesity. Obese women taking contraceptives should be viewed as an ‘at risk’ population, and as such, they should receive advice to change their lifestyle, avoiding other cardiovascular risk factors, as a form of primary prevention. This indication should be extended to young women, as data show that COCs should be avoided in obese women of any age.

1 January 2024 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
CVCristiana Vitale
Cristiana Vitale
ISIlaria Spoletini
Ilaria Spoletini
GRGiuseppe Rosano
Giuseppe Rosano
Vitale C, et al. Int J Heart Fail. 2024 Jul;6(3):107-116. https://doi.org/10.36628/ijhf.2023.0057

1 May 2020 in Journal of Cardiovascular Medicine
Verified
Journal Article
Open access
ISIlaria Spoletini
Ilaria Spoletini
RFRoberto Ferrari
Roberto Ferrari
GRGiuseppe M.C. Rosano
Giuseppe M.C. Rosano
Aims: There is evidence that stable angina patients may suffer from emotional disorders that further impair their quality of life. However, the emotional experience of living with stable angina from the patient's perspective still has to be explored. Thus, the main aim of this study was to explore patients’ emotional experience of having stable angina and their reported needs during the pathway from the first symptoms, through the process of diagnosis, to management and related lifestyle changes. Methods: A survey was conducted in 75 chronic ischemic heart disease patients with angina (Brazil, China, Romania, Russia, and Turkey) using a 75-min, face-to-face in-depth interview. Results and Conclusion: Patients’ responses highlighted the need to increase individuals’ awareness on the first signs and symptoms of the disease. The survey also showed that chronic stable angina patients need constant emotional support to overcome stress, anxiety, and depression. Finally, this study suggests the need to offer greater space for dialogue with healthcare professionals to get more comprehensive and ‘patient-friendly’ information.

3 June 2017 in International Cardiovascular Forum Journal
Verified
Journal Article
Open access
PDF file
ISIlaria Spoletini
Ilaria Spoletini
PSPetar Seferovic
Petar Seferovic
Co-morbidities are particularly relevant in the management of HF as they may confound HF diagnosis, worsen symptomatology, impact quality of life and aggravate the prognosis. According to the most recent European Society of Cardiology (ESC) guidelines, treatment of co- morbidities is an essential element of the comprehensive care of HF. Angina and coronary artery disease (CAD), in particular are common disorders associated with HF. The pharmacological and surgical management of angina according to the ESC guidelines is reviewed in this article.

3 June 2017 in International Cardiovascular Forum Journal
Verified
Journal Article
Open access
PDF file
ISIlaria Spoletini
Ilaria Spoletini
ACAndrew Coats
Andrew Coats
It has been long acknowledged that electrical-conduction disturbances may be both a cause of heart failure and a consequence of it. In fact, many patients with heart failure have an asynchronous contraction pattern of the heart muscle that further reduces the heart ability to pump blood. Electrical disturbances may therefore result in progressive left ventricular dysfunction, due to the added effects of HF-related electrical dyssynchrony. For this reason, device therapy may play a key role in the management of patients with heart failure and reduced ejection fraction (HFrEF). In particular, Implantable Cardioverter- Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) may improve ejection fraction by reestablishing mechanical synchrony, possibly reversing symptoms and signs of heart failure, in addition to the more obvious role of ICD in terminating ventricular arrhythmias that threaten sudden death. Recommendations on device therapy from the current guidelines on heart failure management put out by the ESC/HFA in 2016 update our understanding of the evidence base for the use of ICD and CRT in HFrEF. We review these recommendations and the evidence behind them.